These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17139760)

  • 41. White paper. The five myths of generic competition. A Pharma Matters report. March 2009.
    Drug News Perspect; 2009 Apr; 22(3):171-5. PubMed ID: 19440560
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patent infringement. Court denies motion to alter patent claim decision.
    AIDS Policy Law; 2003 Dec; 18(22):6. PubMed ID: 14974399
    [No Abstract]   [Full Text] [Related]  

  • 43. Patent law rulings work in favor of generics.
    Sipkoff M
    Manag Care; 2007 Sep; 16(9):12, 14. PubMed ID: 17969743
    [No Abstract]   [Full Text] [Related]  

  • 44. 'Pay-for-delay' decision may be left to lawmakers.
    Hutson S
    Nat Med; 2010 Oct; 16(10):1052. PubMed ID: 20930721
    [No Abstract]   [Full Text] [Related]  

  • 45. Drugs are scarce as mix of programs aims to ease access.
    Brower V
    J Natl Cancer Inst; 2009 Oct; 101(19):1304-6. PubMed ID: 19755680
    [No Abstract]   [Full Text] [Related]  

  • 46. Brazil and India file complaint against EU over seizure of generic drugs.
    Zarocostas J
    BMJ; 2010 May; 340():c2672. PubMed ID: 20483945
    [No Abstract]   [Full Text] [Related]  

  • 47. Are patent expirations the answer to improving patient adherence?
    Klepser DG
    Am J Manag Care; 2008 Dec; 14(12):787-8. PubMed ID: 19067495
    [No Abstract]   [Full Text] [Related]  

  • 48. Evolution of insulin patents and market exclusivities in the USA.
    Luo J; Kesselheim AS
    Lancet Diabetes Endocrinol; 2015 Nov; 3(11):835-7. PubMed ID: 26453281
    [No Abstract]   [Full Text] [Related]  

  • 49. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mongkol na Songkhla interview. Thai health minister defends controversial drug-patent policy. Interview by Richard Stone.
    Songkhla MN
    Science; 2007 Jun; 316(5830):1408. PubMed ID: 17556557
    [No Abstract]   [Full Text] [Related]  

  • 51. Correcting Hatch-Waxman.
    Fernandes M
    Health Aff (Millwood); 2008; 27(3):902-3; author reply 903. PubMed ID: 18475000
    [No Abstract]   [Full Text] [Related]  

  • 52. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Congress works to permit 'biosimilar' drugs very soon.
    Carroll J
    Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559
    [No Abstract]   [Full Text] [Related]  

  • 54. Authorized generic drugs, price competition, and consumers' welfare.
    Berndt ER; Mortimer R; Bhattacharjya A; Parece A; Tuttle E
    Health Aff (Millwood); 2007; 26(3):790-9. PubMed ID: 17485758
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Issues in the interpretation of 180-day exclusivity.
    Lietzan E; Korn DE
    Food Drug Law J; 2007; 62(1):49-75. PubMed ID: 17444026
    [No Abstract]   [Full Text] [Related]  

  • 56. Overcoming the challenges in the pharma/biotech industry.
    Graul AI; Prous JR
    Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
    [TBL] [Abstract][Full Text] [Related]  

  • 57. More patent protection for medicines with a new purpose.
    Morgan G
    Nature; 2010 Jun; 465(7301):1005. PubMed ID: 20577188
    [No Abstract]   [Full Text] [Related]  

  • 58. Democrats prioritize pricing, generics and drug safety.
    Fox JL
    Nat Biotechnol; 2007 Feb; 25(2):150-1. PubMed ID: 17287735
    [No Abstract]   [Full Text] [Related]  

  • 59. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sluggish generics entry prompts calls for European patent reform.
    Laursen L
    Nat Med; 2009 Nov; 15(11):1239. PubMed ID: 19893542
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.